| Autor: |
Zhang H; Departments of Pharmacology and., Lund DM; Departments of Pharmacology and., Ciccone HA; Departments of Pharmacology and., Staatz WD; Departments of Pharmacology and., Ibrahim MM; Departments of Pharmacology and.; Anesthesiology, College of Medicine, University of Arizona, Tucson, AZ, United States., Largent-Milnes TM; Departments of Pharmacology and., Seltzman HH; Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, United States., Spigelman I; Division of Oral Biology & Medicine, School of Dentistry, University of California, Los Angeles, CA, United States., Vanderah TW; Departments of Pharmacology and. |
| Jazyk: |
angličtina |
| Zdroj: |
Pain [Pain] 2018 Sep; Vol. 159 (9), pp. 1814-1823. |
| DOI: |
10.1097/j.pain.0000000000001278 |
| Abstrakt: |
Many malignant cancers, including breast cancer, have a propensity to invade bones, leading to excruciating bone pain. Opioids are the primary analgesics used to alleviate this cancer-induced bone pain (CIBP) but are associated with numerous severe side effects, including enhanced bone degradation, which significantly impairs patients' quality of life. By contrast, agonists activating only peripheral CB1 receptors (CB1Rs) have been shown to effectively alleviate multiple chronic pain conditions with limited side effects, yet no studies have evaluated their role(s) in CIBP. Here, we demonstrate for the first time that a peripherally selective CB1R agonist can effectively suppress CIBP. Our studies using a syngeneic murine model of CIBP show that both acute and sustained administration of a peripherally restricted CB1R agonist, 4-{2-[-(1E)-1[(4-propylnaphthalen-1-yl)methylidene]-1H-inden-3-yl]ethyl}morpholine (PrNMI), significantly alleviated spontaneous pain behaviors in the animals. This analgesic effect by PrNMI can be reversed by a systemic administration but not spinal injection of SR141716, a selective CB1R antagonist. In addition, the cancer-induced bone loss in the animals was not exacerbated by a repeated administration of PrNMI. Furthermore, catalepsy and hypothermia, the common side effects induced by cannabinoids, were measured at the supratherapeutic doses of PrNMI tested. PrNMI induced mild sedation, yet no anxiety or a decrease in limb movements was detected. Overall, our studies demonstrate that CIBP can be effectively managed by using a peripherally restricted CB1R agonist, PrNMI, without inducing dose-limiting central side effects. Thus, targeting peripheral CB1Rs could be an alternative therapeutic strategy for the treatment of CIBP. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
